{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year. Relapse was defined as per standard PCNSL criteria from clinical and MRI criteria.","groups":[{"description":"Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy\n\nHigh-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide","id":"OG000","title":"High-dose Chemotherapy With Autologous Stem Cell Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The participant that was lost to follow-up was not available for analysis.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year","type":"PRIMARY","unitOfMeasure":"Participants"}